SCHEMBL427653

SCHEMBL427653

CN(Cc1ccccc1)C(=O)n1cnc(-c2ccc(Oc3ccc(C(N)=O)cc3)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 2/20 0.44
ABHD6 Q9BV23 1/20 0.43
MGLL Q99685 2/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
AOC3 Q16853 2/20 0.40
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RORC P51449 2/20 0.40
FYN P06241 1/20 0.40
GRK5 P34947 1/20 0.40
ACHE P22303 1/20 0.40
CHEK2 O96017 1/20 0.39
APOBEC3A P31941 1/20 0.39
TNK2 Q07912 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425582 0.84 PARP10 (0.47) PARP10MGLLKMT2AALDH1A1SMN1; SMN2
SCHEMBL426879 0.84 PARP10 (0.47) PARP10MGLLKMT2AALDH1A1SMN1; SMN2
SCHEMBL427450 0.80 TRPV1 (0.48) MGLLMEN1KMT2AOPRM1ALDH1A1
SCHEMBL426863 0.72 HDAC1 (0.44) MEN1KMT2AALDH1A1SMN1; SMN2APOBEC3A
SCHEMBL426884 0.71 PARP10 (0.56) PARP10MGLLMEN1KMT2AALDH1A1
SCHEMBL425651 0.71 APOBEC3A (0.43) MEN1KMT2AALDH1A1APOBEC3A
SCHEMBL2179538 0.69 BCHE (0.48) MGLLMEN1KMT2AALDH1A1ACHE
SCHEMBL424347 0.69 LIPE (0.56) MGLLKMT2AALDH1A1SMN1; SMN2ACHE
SCHEMBL425561 0.68 MGLL (0.46) PARP10MGLLMEN1KMT2A
SCHEMBL8739023 0.68 MEN1 (0.76) MEN1KMT2AAOC3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 PARP10 1582/4885ABHD6 32/4885MGLL 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.